

**REVISED 9/3/2014**

**Preferred Drug List Committee  
Meeting Agenda, Open Session  
September 10th, 2014 10:00 a.m.**

**Meeting Location**

HP Enterprise Services ~ Capital Room  
6511 SE Forbes Ave., Bldg. 283 J, Topeka, Kansas 66619

**Board Members**

Taylor Gill, Pharm.D., BCPS	Robert Haneke, Pharm.D.
Janet Hierl, R.Ph.	Emily Prohaska, Pharm.D., BCACP
Matthew Schlotterback, M.D.	Donna Sweet, M.D.
Dennis Tietze, M.D.	

**KDHE-DHCF Staff**

Carol Arace	F.E. Bustillo, III, M.D.
Kelley Melton, Pharm.D.	Liane Larson, MPH, Pharm.D.

**HP Enterprise Services / HID Staff**

Karen Kluczykowski, R.Ph.	Nicole Ellermeier, Pharm.D.
---------------------------	-----------------------------

- I. Welcome & Announcements
- II. Review & Approval of March 13th, 2014 Meeting Minutes
- III. Insulin Delivery Systems – Class Re-review: New Agent (Novolog FlexTouch)
  - a. Public Comment\*
  - b. Committee Discussion/Recommendations
- IV. Long-Acting Insulins –Class Re-review: New Agents (Levemir FlexPen, Levemir FlexTouch, Lantus SoloStar)
  - a. Public Comment\*
  - b. Committee Discussion/Recommendations
- V. Hypertriglyceridemia Agents –Class Re-review: New Agents (Epanova, Omtryg)
  - a. Public Comment\*
  - b. Committee Discussion/Recommendations
- VI. Incretin Mimetics – Class Re-review: New Agents (Bydureon Pen, Tanzeum)

- a. Public Comment\*
  - b. Committee Discussion/Recommendations
- VII. Combination Products for Hyperlipidemia – New Class Review (Liptruzet, Vytorin)
- a. Public Comment\*
  - b. Committee Discussion/Recommendations
- VIII. Non-Steroidal Anti-Inflammatory Drugs (Oral)– Class Re-review: New Agent (Tivorbex)
- a. Public Comment\*
  - b. Committee Discussion/Recommendations
- IX. Anticholinergics for the Maintenance Treatment of COPD – Class Re-review: (Anoro Ellipta, Incruse Ellipta)
- a. Public Comment\*
  - b. Committee Discussion/Recommendations
- X. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors – Class Re-review: New Agent (Jardiance)
- a. Public Comment\*
  - b. Committee Discussion/Recommendations
- XI. Biologics – Class Re-review: New Indications/Agents (Cimzia: Psoriatic Arthritis, Ankylosing Spondylitis; Entyvio: Crohn’s Disease, Ulcerative Colitis; Otezla: Psoriatic Arthritis; Xeljanz: Adult Rheumatoid Arthritis)
- a. Public Comment\*
  - b. Committee Discussion/Recommendations
- XII. Inhaled Long-Acting Beta2-Agonists – Class Re-review: New Agent (Striverdi Respimat)
- a. Public Comment\*
  - b. Committee Discussion/Recommendations
- XIII. Ophthalmic Prostaglandin Analogs – Class Re-review: New Agent (Izba)
- a. Public Comment\*
  - b. Committee Discussion/Recommendations
- XIV. Combination Products for Diabetes – Class Re-review: New Agent (Invokamet)
- a. Public Comment\*
  - b. Committee Discussion/Recommendations

\*Public Comment is limited to five minutes per product; additional time will be allowed at the Board’s discretion. Informal comments will be accepted from members of the audience at various points in the agenda.

**\*\*THIS AGENDA IS SUBJECT TO CHANGE.**

XV. Otic Combinations – New Class Review (Acetasol HC, A/B Otic, Cortisporin, Ciprodex, Cipro HC, Cortisporin TC)

- a. Public Comment\*
- b. Committee Discussion/Recommendations

XVI. Open Public Comment

XVII. Adjourn

\*Public Comment is limited to five minutes per product; additional time will be allowed at the Board's discretion. Informal comments will be accepted from members of the audience at various points in the agenda.

**\*\*THIS AGENDA IS SUBJECT TO CHANGE.**